Today, Incyte (NASDAQ: INCY) announced that the FDA had approved their blood cancer drug Jakafi that's designed to treat myelofibrosis. The drug is the first to be approved to treat...(read more
We are maintaining our Neutral recommendation on Incyte Corporation (INCY) with a target price of $18.00.
Incyte is a Wilmington, Delaware-based drug discovery and...(read more
Yesterday we showed you the Boxer Shorts and what they were doing. Certainly there are a lot of negative looking charts, but there are still a lot of bullish ones. Despite the fact that the market had some difficult sessions the last few days, w...